文献速递胃肠动力与功能性疾病

肠易激综合征腹痛的饮食与药物治疗

Dietary and pharmacological treatment of abdominal pain in IBS.
PubMed 文献 · Gut · 2017-02-23

本综述介绍内脏感觉原理,并评价功能性胃肠病(主要为肠易激综合征)内脏痛管理的现有方法,包括膳食措施(补充纤维、低FODMAP饮食)和药物(解痉药、薄荷油、抗抑郁药、5-HT3受体拮抗剂、利福昔明、促分泌药、μ/κ阿片受体激动剂与δ阿片受体拮抗剂、H1受体拮抗剂、神经激肽-2受体拮抗剂、GABA能药物),基于关键试验或已发表系统评价与Meta分析讨论疗效与安全性,以OR或相对危险度及95%CI表示。

要点

  • 低FODMAP饮食及多种药物可用于肠易激综合征内脏痛管理。
  • 疗效与安全性证据来自关键试验或系统评价与Meta分析。
  • 潜在新方法可能基于黏膜基因表达、microRNA及表观遗传标志物。

核心结论

  • 本综述评价了膳食措施和多种药物对功能性胃肠病(主要为肠易激综合征)内脏痛的疗效,基于关键试验或已发表系统评价与Meta分析,以OR或相对危险度及95%CI表示。

研究设计与样本

  • 本综述介绍内脏感觉的生理与解剖,并评价多种疗法缓解内脏痛(典型为肠易激综合征)的疗效。

主要发现

  • 膳食措施包括补充纤维和低可发酵寡糖、二糖、单糖和多元醇(FODMAP)饮食。
  • 药物包括解痉药、薄荷油、抗抑郁药(三环类、选择性5-羟色胺再摄取抑制剂)、5-HT3受体拮抗剂(阿洛司琼、昂丹司琼、雷莫司琼)、非吸收性抗生素(利福昔明)、促分泌药(鲁比前列酮、利那洛肽)、μ阿片受体和κ阿片受体激动剂及δ阿片受体拮抗剂(艾沙度林)、组胺H1受体拮抗剂(依巴斯汀)、神经激肽-2受体拮抗剂(伊波度坦)和GABA能药物(加巴喷丁和普瑞巴林)。
  • 潜在新方法可能基于近期对人活检和动物内脏高敏感模型中黏膜基因表达、microRNA和表观遗传标志物的认识。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This review introduces the principles of visceral sensation and appraises the current approaches to management of visceral pain in functional GI diseases, principally IBS. These approaches include dietary measures including fibre supplementation, low fermentable oligosaccharides, disaccharides, monosaccharides and polyols diet, and pharmacological approaches such as antispasmodics, peppermint oil, antidepressants (tricyclic agents, selective serotonin reuptake inhibitors), 5-HT3 receptor antagonists (alosetron, ondansetron, ramosetron), non-absorbed antibiotic (rifaximin), secretagogues (lubiprostone, linaclotide), μ-opioid receptor (OR) and κ-OR agonist, δ-OR antagonist (eluxadoline), histamine H1 receptor antagonist (ebastine), neurokinin-2 receptor antagonist (ibodutant) and GABAergic agents (gabapentin and pregabalin). Efficacy and safety are discussed based on pivotal trials or published systematic reviews and meta-analysis, expressing ORs or relative risks and their 95% CIs. Potential new approaches may be based on recent insights on mucosal expression of genes, and microRNA and epigenetic markers in human biopsies and in animal models of visceral hypersensitivity.The objectives of this review are to appraise the physiology and anatomy of gut sensation and the efficacy in the relief of visceral pain (typically in IBS) of several classes of therapies. These include fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and different classes of medications (box 1). Box 1Classes of pharmacological agents for visceral painAntidepressants (tricyclic agents, selective serotonin reuptake inhibitors)Peppermint oil5-HT3 receptor antagonists (alosetron, ondansetron, ramosetron)Non-absorbed antibiotic (rifaximin)Secretagogues (lubiprostone, linaclotide)μ-Opioid receptor (OR) and κ-OR agonist and δ-OR antagonist (eluxadoline)Histamine H1 receptor antagonist (ebastine)Neurokinin-2 receptor antagonist (ibodutant)GABAergic agents (gabapentin and pregabalin).

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Camilleri M, Boeckxstaens G. Dietary and pharmacological treatment of abdominal pain in IBS. Gut. 2017. PMID: 28232472. doi:10.1136/gutjnl-2016-313425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。